Leerink Partners initiated coverage on Tenaya Therapeutics with a new price target

11/30/23 7:50:26 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Leerink Partners initiated coverage of Tenaya Therapeutics with a rating of Outperform and set a new price target of $7.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TNYA

Date	Price Target	Rating	Analyst
6/10/2024		Outperform	William Blair
11/30/2023	$7.00	Outperform	Leerink Partners
6/15/2022	$25.00	Buy	H.C. Wainwright
8/24/2021		Outperform	Cowen & Co.
8/24/2021	$31.00	Overweight	Morgan Stanley
8/24/2021	$37.00	Buy	Chardan Capital
8/24/2021	$40.00	Overweight	Piper Sandler